We found that, in HER2-positive breast cancer, the TIL counts in post-NAT tissues were increased, but PD-L1+TC was decreased, suggesting that neoadjuvant trastuzumab plus chemotherapy may activate the antitumor immune response, thereby inhibiting tumor immune escape. This evidence concerns the gene ERBB2 and breast cancer.